Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 9 search results for "Gilotrif" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
NSCLC Targeted Therapy: 8 Facts
... Targeted Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) ...
NSCLC Targeted Therapy: 8 Facts
... Targeted Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) ...
EGFR-Positive Lung Cancer: 5 Facts To Know
... Second-generation TKIs include dacomitinib (Vizimpro) and afatinib (Gilotrif), which may be more effective than first-generation TKIs.Additionally, the third-generation TKI osimertinib (Tagrisso) may be suggested for people whose cancer didn’t respond after treatment with first-generation TKIs. ...
EGFR-Positive Lung Cancer: 5 Facts To Know
... Second-generation TKIs include dacomitinib (Vizimpro) and afatinib (Gilotrif), which may be more effective than first-generation TKIs.Additionally, the third-generation TKI osimertinib (Tagrisso) may be suggested for people whose cancer didn’t respond after treatment with first-generation TKIs. ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... first-line treatment for certain genetic mutations.The many types of targeted therapies for NSCLC include: Vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab (Avastin) and ramucirumab (Cyramza) KRAS inhibitors, such as adagrasib (Krazati) and sotorasib (Lumakras) Epidermal growth factor receptor (EGFR) inhibitors, such as afatinib (Gilotrif ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... first-line treatment for certain genetic mutations.The many types of targeted therapies for NSCLC include: Vascular endothelial growth factor (VEGF) inhibitors, such as bevacizumab (Avastin) and ramucirumab (Cyramza) KRAS inhibitors, such as adagrasib (Krazati) and sotorasib (Lumakras) Epidermal growth factor receptor (EGFR) inhibitors, such as afatinib (Gilotrif ...
What Is Advanced NSCLC? Symptoms, Treatment, Stages, and More
... effects than traditional chemotherapy.Classes of targeted therapy for advanced NSCLC include tyrosine kinase inhibitors, antibody-drug conjugates (ADCs), and angiogenesis inhibitors, which work in different ways to slow the growth or encourage the death of lung cancer cells.Many targeted therapy drugs may be used to treat NSCLC, including: Afatinib (Gilotrif ...
What Is Advanced NSCLC? Symptoms, Treatment, Stages, and More
... effects than traditional chemotherapy.Classes of targeted therapy for advanced NSCLC include tyrosine kinase inhibitors, antibody-drug conjugates (ADCs), and angiogenesis inhibitors, which work in different ways to slow the growth or encourage the death of lung cancer cells.Many targeted therapy drugs may be used to treat NSCLC, including: Afatinib (Gilotrif ...
6 Lung Cancer Mutations and Treatments That Target Them
... Food and Drug Administration (FDA) for lung cancers containing EGFR mutations: Erlotinib (Tarceva) Gefitinib (Iressa) Afatinib (Gilotrif) Dacomitinib (Vizimpro) Osimertinib (Tagrisso) You can learn more about these medications and other treatments for lung cancer here.2. ...
6 Lung Cancer Mutations and Treatments That Target Them
... Food and Drug Administration (FDA) for lung cancers containing EGFR mutations: Erlotinib (Tarceva) Gefitinib (Iressa) Afatinib (Gilotrif) Dacomitinib (Vizimpro) Osimertinib (Tagrisso) You can learn more about these medications and other treatments for lung cancer here.2. ...
5 Treatment Types for Advanced NSCLC
... Several new drugs have been approved for treating NSCLC containing specific mutations.For EGFR mutations, the approved treatments include: Afatinib (Gilotrif) Erlotinib Gefitinib (Iressa) Osimertinib (Tagrisso) For EML4-ALK fusions, available treatments include: Alectinib (Alecensa) Crizotinib (Xalkori) Ceritinib (Zykadia) For KRAS mutations, options ...
5 Treatment Types for Advanced NSCLC
... Several new drugs have been approved for treating NSCLC containing specific mutations.For EGFR mutations, the approved treatments include: Afatinib (Gilotrif) Erlotinib Gefitinib (Iressa) Osimertinib (Tagrisso) For EML4-ALK fusions, available treatments include: Alectinib (Alecensa) Crizotinib (Xalkori) Ceritinib (Zykadia) For KRAS mutations, options ...
Biomarkers for Lung Cancer: 12 Things To Know
... These mutations help cancer cells grow and divide.Several FDA-approved treatments are available for NSCLC tumors with EGFR mutations, including: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Necitumumab (Portrazza) Osimertinib (Tagrisso) Ramucirumab (Cyramza) Sunvozertinib (Zegfrovy) Some EGFR Treatments Depend on ...
Biomarkers for Lung Cancer: 12 Things To Know
... These mutations help cancer cells grow and divide.Several FDA-approved treatments are available for NSCLC tumors with EGFR mutations, including: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Necitumumab (Portrazza) Osimertinib (Tagrisso) Ramucirumab (Cyramza) Sunvozertinib (Zegfrovy) Some EGFR Treatments Depend on ...
Lung Cancer Treatment Options
... Small molecular inhibitors have been developed to target EGFR mutations, such as: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Erlotinib Gefitinib Lazertinib (Lazcluze) Necitumumab (Portrazza) Sunvozertinib (Zegfrovy) These small molecular inhibitors can shrink tumors for an extended period. ...
Lung Cancer Treatment Options
... Small molecular inhibitors have been developed to target EGFR mutations, such as: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Erlotinib Gefitinib Lazertinib (Lazcluze) Necitumumab (Portrazza) Sunvozertinib (Zegfrovy) These small molecular inhibitors can shrink tumors for an extended period. ...
How Does Targeted Therapy for Lung Cancer Work?
... TKIs for EGFR mutations include: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib Gefitinib (Iressa) Osimertinib (Tagrisso) is often used when a person’s cancer becomes resistant to earlier-generation EGFR inhibitors. More recently, osimertinib also was approved as a first-line treatment for some people with EGFR-mutated NSCLC. ...
How Does Targeted Therapy for Lung Cancer Work?
... TKIs for EGFR mutations include: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib Gefitinib (Iressa) Osimertinib (Tagrisso) is often used when a person’s cancer becomes resistant to earlier-generation EGFR inhibitors. More recently, osimertinib also was approved as a first-line treatment for some people with EGFR-mutated NSCLC. ...